

Receipt date: 08/11/2008

Docket No.: RLL-293US

Serial No.: 10/552,456

**INFORMATION DISCLOSURE CITATION**Applicants: MEHTA *et al.*

Filed: 10/7/2005

Group: 1626

SUPPLEMENTAL

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/J.N./	S1A1	2,490,714	12/6/1949	Searle	260	239	
	S1A2	5,001,160	3/19/1991	McPherson <i>et al.</i>	514	255	
	S1A3	5,164,402	11/17/1992	Brighty	514	300	
	S1A4	5,179,108	1/12/1993	George <i>et al.</i>	514	319	
	S1A5	6,313,312	11/6/2001	Banks <i>et al.</i>	548	452	
	S1A6	7,288,562	10/30/2007	Mehta <i>et al.</i>	514	412	
	S1A7	2003/0105071	6/5/2003	Cuny <i>et al.</i>	514	210.2	
	S1A8	2003/0162780	8/28/2003	Brotherton-Pleiss <i>et al.</i>	514	235.5	
	S1A9	2003/0171362	9/11/2003	Madera <i>et al.</i>	514	218	
	S1A10	2006/0287380	12/21/2006	Salman <i>et al.</i>	514	412	

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES   NO	
/J.N./	S1B1	CA 2,155,320	8/19/1993	Canada	C07D	211/68		
	S1B2	EP 0 413 455	2/20/1991	EPO	C07D	401/04		
	S1B3	EP 0 613 232	8/31/1994	EPO	H02M	3/335		
	S1B4	EP 0 863 141	9/9/1998	EPO	C07D	401/06		
	S1B5	EP 0 930 298	7/21/1999	EPO	C07D	211/46		
	S1B6	WO 98/53814	12/3/1998	PCT	A61K	31/395		
	S1B7	WO 99/43657	9/2/1999	PCT	C07D	211/26		
	S1B8	WO 01/42212	6/14/2001	PCT	C07D	211/48		

EXAMINER

/Jason Nolan/

DATE CONSIDERED

09/12/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Receipt date: 08/11/2008

Docket No.: RLL-293US

Serial No.: 10/552,456

**INFORMATION DISCLOSURE CITATION**Applicants: MEHTA *et al.*

SUPPLEMENTAL

Filed: 10/7/2005

Group: 1626

/J.N./	S1B9	WO 01/42213	6/14/2001	PCT	C07D	211/58	
	S1B10	WO 01/47893	7/5/2001	PCT	C07D	221/24	
	S1B11	WO 01/90081	11/29/2001	PCT	C07D	241/08	
	S1B12	WO 01/90082	11/29/2001	PCT	C07D	241/08	
	S1B13	WO 02/00652	1/3/2002	PCT	C07D	453/02	
	S1B14	WO 02/04402	1/17/2002	PCT	C07C	219/10	
	S1B15	WO 02/006241	1/24/2002	PCT	C07D	223/16	
	S1B16	WO 02/051841	7/4/2002	PCT	C07D	453/02	
	S1B17	WO 02/053564	7/11/2002	PCT	C07D	453/02	
	S1B18	WO 03/033495	4/24/2003	PCT	C07D	453/02	
	S1B19	WO 03/048124	6/12/2003	PCT	C07D	211/26	
	S1B20	WO 03/048125	6/12/2003	PCT	C07D	211/58	
	S1B21	WO 2004/004629	1/15/2004	PCT	A61K		
	S1B22	WO 2004/005252	1/15/2004	PCT	C07D	209/52	
	S1B23	WO 2004/014363	2/19/2004	PCT	A61K	31/40	
	S1B24	WO 2004/014853	2/19/2004	PCT	C07D	209/02	
	S1B25	WO 2004/018422	3/4/2004	PCT	C07D	209/52	
	S1B26	WO 2004/052857	6/24/2004	PCT	C07D	209/52	
	S1B27	WO 2004/056767	7/8/2004	PCT	C07D	207/14	
	S1B28	WO 2004/056810	7/8/2004	PCT	C07D	405/12	
	S1B29	WO 2004/056811	7/8/2004	PCT	C07D	405/12	
	S1B30	WO 2004/067510	8/12/2004	PCT	C07D	209/52	
	S1B31	WO 2004/069835	8/19/2004	PCT	C07D	471/08	
	S1B32	WO 2004/089363	10/21/2004	PCT	A61K	31/403	
	S1B33	WO 2004/089899	10/21/2004	PCT	C07D	209/52	
	S1B34	WO 2004/089900	10/21/2004	PCT	C07D	209/52	
	S1B35	WO 2005/092341	10/6/2005	PCT	A61K	31/496	

EXAMINER

/Jason Nolan/

DATE CONSIDERED

09/12/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Receipt date: 08/11/2008		Docket No.: RLL-293US	Serial No.: 10/552,456
<b>INFORMATION DISCLOSURE CITATION</b>  SUPPLEMENTAL		Applicants: MEHTA <i>et al.</i>	
		Filed: 10/7/2005	Group: 1626

/J.N./	S1B36	WO 2006/003587	1/12/2006	PCT	A61K	9/16	
/J.N./	S1B37	WO 2006/035282	4/6/2006	PCT	A61K	31/439	
/J.N./	S1B38	WO 2006/064304	6/22/2006	PCT	C07D	209/52	

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

/J.N./	S1C1	Brighty <i>et al.</i> , "Synthesis of (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-6-Amino-3-azabicyclo[3.1.0]hexane, a Novel Achiral Diamine", <i>Synlett</i> , 1097-1099 (1996)
	S1C2	Grover <i>et al.</i> , "Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis", <i>Journal of Organic Chemistry</i> , <u>65</u> :6283-6287 (2000)
	S1C3	Shacklett and Smith, "The Preparation of Substituted Benzoic Acids", <i>Journal of the American Chemical Society</i> , <u>75</u> :2654-2657 (1953)
	S1C4	Nkpa and Chedekel, "Mechanistic Studies on the Addition of Cysteine to 3,4-Dihydroxyphenylalanine", <i>Journal of Organic Chemistry</i> , <u>46</u> :213-215 (1981)
	S1C5	Kadin and Cannon, "Esters of N-Methyl-3-hydroxypiperidine Having Psychotomimetic Activity. II", <i>Journal of Organic Chemistry</i> , <u>27</u> :240-245 (1962)
	S1C6	Weinstock <i>et al.</i> , "A General, One-Step Synthesis of $\alpha$ -keto Esters", <i>Synthetic Communications</i> , <u>11</u> (12):943-946 (1981)
	S1C7	Vogel <i>et al.</i> , 1996. <i>Vogel's Textbook of Practical Organic Chemistry</i> . 5th Edition. USA: Prentice Hall, 1046-1047.
	S1C8	Bundgaard, H., 1985. <i>Design of Prodrugs</i> . Elsevier.
	S1C9	Kaiser <i>et al.</i> , "Synthesis and Antimuscarinic Activity of Some 1-Cycloalkyl-1-hydroxy-1-phenyl-3-(4-substituted piperazinyl)-2-propanones and Related Compounds", <i>Journal of Medicinal Chemistry</i> , <u>36</u> (5):610-616 (1993)
	S1C10	Carter <i>et al.</i> , "Analogues of Oxybutynin. Synthesis and Antimuscarinic and Bladder Activity of Some Substituted 7-Amino-1-hydroxy-5-heptyn-2-ones and Related Compounds", <i>Journal of Medicinal Chemistry</i> , <u>34</u> (10):3065-3074 (1991)
	S1C11	Wess <i>et al.</i> , "Muscarinic receptor subtypes mediating central and peripheral antinociception studied with muscarinic receptor knockout mice: A review", <i>Life Sciences</i> , <u>72</u> :2047-2054 (2003)
	S1C12	O'Neill, "Unusual suspect for antipsychotic-induced diabetes", <i>Drug Discovery Today</i> , <u>10</u> (20):1338 (2005)
	S1C13	Michel and Hegde, "Treatment of the overactive bladder syndrome with muscarinic receptor antagonists - a matter of metabolites?", <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> , <u>374</u> :79-85 (2006)

EXAMINER	/Jason Nolan/	DATE CONSIDERED	09/12/2008
----------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Receipt date: 08/11/2008

Docket No.: RLL-293US

Serial No.: 10/552,456

# INFORMATION DISCLOSURE CITATION

Applicants: MEHTA *et al.*

SUPPLEMENTAL

Filed: 10/7/2005

Group: 1626

/J.N./	S1C14	Latifpour <i>et al.</i> , "Effects of Experimental Diabetes on Biochemical and Functional Characteristics of Bladder Muscarinic Receptors", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , <u>248</u> (1):81-88 (1989)
/J.N./	S1C15	Carrier and Aronstam, "Altered Muscarinic Receptor Properties and Function in the Heart in Diabetes", <i>The Journal of Pharmacology and Experimental Therapeutics</i> , <u>242</u> (2):531-535 (1987)
/J.N./	S1C16	Ahrén <i>et al.</i> , "Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse", <i>Diabetologia</i> , <u>39</u> :383-390 (1996)
/J.N./	S1C17	Abrams <i>et al.</i> , "Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder", <i>British Journal of Pharmacology</i> , <u>148</u> (5):565-578 (2006)

EXAMINER

/Jason Nolan/

DATE CONSIDERED

09/12/2008

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.